Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Arterial Hypertension
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 25, No 1 (2021)
Original paper
Published online: 2021-02-02
View PDF Download PDF file
Get Citation

Blood pressure lowering effects of alpha-lipoic acid supplementation: a meta-analysis of randomized controlled trials

Virginia Boccardi1, Mohsen Taghizadeh2, Mina Salek2, Sadegh Jafarnejad2
DOI: 10.5603/AH.a2021.0001
·
Arterial Hypertension 2021;25(1):29-38.
Affiliations
  1. Santa Maria della Misericordia Hospital, Section of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Italy
  2. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran

open access

Vol 25, No 1 (2021)
ORIGINAL PAPERS
Published online: 2021-02-02

Abstract

Background: The aim of the present meta-analysis was to detect the effect of a-lipoic acid (ALA) supplementation
on systolic and diastolic blood pressure (BP).

Material and methods: The related records were selected from several electronic databases from the earliest date 1980 until October 2019. The heterogeneities were assessed by I2 test (I2 < 50%) and X2 test on Cochrane’s Q statistic. Standardized mean difference (SMD) and their 95% confidence intervals (CIs) were considered for net change in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Subgroup analyses were also conducted by baseline BP, health status, doses of supplementation, study duration and supplement utilization.

Results: As a result, a total of 10 studies with 612 subjects were included in the final analysis. Alpha-lipoic acid supplementation significantly reduced SBP (SMD = –0.50, 95% CI: –0.84, –0.16, p = 0.004) and DBP (SMD = –0.40, 95% CI: –0.71, –0.09, p = 0.01), compared to the controls, with the reduction of 6.1 mm Hg and 3.6 mm Hg of the mean SBP and DBP, respectively. Heterogeneities were explored in both SBP and DBP. Moreover, a statistically significant reduction in BP was detected in elevated BP and hypertensive patients as compared with the normotensive subjects.

Conclusion: ALA supplementation could be considered as a BP-lowering agent, especially in subjects with higher blood pressure.

Abstract

Background: The aim of the present meta-analysis was to detect the effect of a-lipoic acid (ALA) supplementation
on systolic and diastolic blood pressure (BP).

Material and methods: The related records were selected from several electronic databases from the earliest date 1980 until October 2019. The heterogeneities were assessed by I2 test (I2 < 50%) and X2 test on Cochrane’s Q statistic. Standardized mean difference (SMD) and their 95% confidence intervals (CIs) were considered for net change in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Subgroup analyses were also conducted by baseline BP, health status, doses of supplementation, study duration and supplement utilization.

Results: As a result, a total of 10 studies with 612 subjects were included in the final analysis. Alpha-lipoic acid supplementation significantly reduced SBP (SMD = –0.50, 95% CI: –0.84, –0.16, p = 0.004) and DBP (SMD = –0.40, 95% CI: –0.71, –0.09, p = 0.01), compared to the controls, with the reduction of 6.1 mm Hg and 3.6 mm Hg of the mean SBP and DBP, respectively. Heterogeneities were explored in both SBP and DBP. Moreover, a statistically significant reduction in BP was detected in elevated BP and hypertensive patients as compared with the normotensive subjects.

Conclusion: ALA supplementation could be considered as a BP-lowering agent, especially in subjects with higher blood pressure.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

α-lipoic acid; blood pressure; systematic review; meta-analysis; RCT

About this article
Title

Blood pressure lowering effects of alpha-lipoic acid supplementation: a meta-analysis of randomized controlled trials

Journal

Arterial Hypertension

Issue

Vol 25, No 1 (2021)

Article type

Original paper

Pages

29-38

Published online

2021-02-02

Page views

7896

Article views/downloads

2716

DOI

10.5603/AH.a2021.0001

Bibliographic record

Arterial Hypertension 2021;25(1):29-38.

Keywords

α-lipoic acid
blood pressure
systematic review
meta-analysis
RCT

Authors

Virginia Boccardi
Mohsen Taghizadeh
Mina Salek
Sadegh Jafarnejad

References (39)
  1. Smith AR, Shenvi SV, Widlansky M, et al. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem. 2004; 11(9): 1135–1146.
    CrossRefPubMed
  2. Brownlee M, Aiello LP, Cooer ME. Complications of Diabetes Mellitus. In: Melmed S, Polonsky KS, Larsen PR. ed. Williams Textbook of Endocrinology. 13 ed. Content Reository Only!, Philadelhia 2016: 1484–581.
  3. Shamsizadeh A, Roohbakhsh A, Ayoobi F. The Role of Natural Products in the Prevention and Treatment of Multiple Sclerosis. In: Watson RR, Killgore W. ed. Nutrition and Lifestyle in Neurological Autoimmune Diseases. Academic Press 2017: 249–60.
  4. Mohammadi V, Dehghani S, Askari G. Does Alpha-lipoic Acid Supplement Regulate Blood Pressure? A Systematic Review of Randomized, Double-blind Placebo-controlled Clinical Trials. Int J Prev Med. 2017; 8: 33.
    CrossRefPubMed
  5. Moini H, Packer L, Saris NEL. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol. 2002; 182(1): 84–90.
    CrossRefPubMed
  6. Skibska B, Goraca A. The protective effect of lipoic acid on selected cardiovascular diseases caused by age-related oxidative stress. Oxid Med Cell Longev. 2015; 2015: 313021.
    CrossRefPubMed
  7. Badran M, Abuyassin B, Golbidi S, et al. Alpha Lipoic Acid Improves Endothelial Function and Oxidative Stress in Mice Exposed to Chronic Intermittent Hypoxia. Oxid Med Cell Longev. 2019; 2019: 4093018.
    CrossRefPubMed
  8. Ergür BU, Çilaker Mıcılı S, Yılmaz O, et al. The effects of α-lipoic acid on aortic injury and hypertension in the rat remnant kidney (5/6 nephrectomy) model. Anatol J Cardiol. 2015; 15(6): 443–449.
    CrossRefPubMed
  9. El Midaoui A, de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension. 2002; 39(2): 303–307.
    CrossRefPubMed
  10. Dorans KS, Mills KT, Liu Y, et al. Trends in Prevalence and Control of Hypertension According to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline. J Am Heart Assoc. 2018; 7(11).
    CrossRefPubMed
  11. Antonakoudis G, Poulimenos L, Kifnidis K, et al. Blood pressure control and cardiovascular risk reduction. Hippokratia. 2007; 11(3): 114–119.
    PubMed
  12. Mohammadi V, Khalili M, Eghtesadi S, et al. The effect of alpha-lipoic acid (ALA) supplementation on cardiovascular risk factors in men with chronic spinal cord injury: a clinical trial. Spinal Cord. 2015; 53(8): 621–624.
    CrossRefPubMed
  13. Noori N, Tabibi H, Hosseinpanah F, et al. Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy. Int J Vitam Nutr Res. 2013; 83(2): 77–85.
    CrossRefPubMed
  14. Mazloom Z, Ansar H. The effect of alpha-lipoic acid on blood pressure in type 2 diabetics. Iran J Endocrinol Metab. 2009; 11(3).
  15. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997; 20(3): 369–373.
    CrossRefPubMed
  16. Koh EH, Lee WJe, Lee SAh, et al. Effects of alpha-lipoic acid on body weight in obese subjects. Am J Med. 2011; 124(1): 85.e1–85.e8.
    CrossRefPubMed
  17. Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4): 264–9, W64.
    CrossRefPubMed
  18. Gopalakrishnan S, Ganeshkumar P. Systematic Reviews and Meta-analysis: Understanding the Best Evidence in Primary Healthcare. J Family Med Prim Care. 2013; 2(1): 9–14.
    CrossRefPubMed
  19. Jafarnejad S, Tsang C, Taghizadeh M, et al. A meta-analysis of cumin ( Cuminum cyminim L.) consumption on metabolic and anthropometric indices in overweight and type 2 diabetics. J Funct Foods. 2018; 44: 313–321.
    CrossRef
  20. Lukaszuk J, Schultz T, Prawitz A, et al. Effects of R-Alpha Lipoic Acid on HbA1c, Lipids and Blood Pressure in Type-2 Diabetics: A Preliminary Study. J Complement Integrat Med. 2009; 6(1).
    CrossRef
  21. Pourghasem Ga, Aliasghari F, Kolahi S, et al. Effects of alpha-lipoic acid supplementation on blood pressure and some inflammatory factors in women with rheumatoid arthritis. Arak Medical University Journal (AMUJ). 2015; 17(93): 9–18.
  22. McMackin CJ, Widlansky ME, Hamburg NM, et al. Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich). 2007; 9(4): 249–255.
    CrossRefPubMed
  23. Tromba L, Perla FM, Carbotta G, et al. Effect of Alpha-Lipoic Acid Supplementation on Endothelial Function and Cardiovascular Risk Factors in Overweight/Obese Youths: A Double-Blind, Placebo-Controlled Randomized Trial. Nutrients. 2019; 11(2).
    CrossRefPubMed
  24. Mohammadi V, Khorvash F, Feizi A, et al. Does Alpha-lipoic Acid Supplementation Modulate Cardiovascular Risk Factors in Patients with Stroke? A Randomized, Double-blind Clinical Trial. Int J Prev Med. 2018; 9: 34.
    CrossRefPubMed
  25. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71(19): e127–e248.
    CrossRefPubMed
  26. Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001; 358(9294): 1682–1686.
    CrossRefPubMed
  27. Franco OH, Peeters A, Bonneux L, et al. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension. 2005; 46(2): 280–286.
    CrossRefPubMed
  28. Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005; 28(5): 385–407.
    CrossRefPubMed
  29. Rodrigo R, Prat H, Passalacqua W, et al. Relationship between oxidative stress and essential hypertension. Hypertens Res. 2007; 30(12): 1159–1167.
    CrossRefPubMed
  30. Senoner T, Dichtl W. Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? Nutrients. 2019; 11(9).
    CrossRefPubMed
  31. Favero G, Paganelli C, Buffoli B, et al. Endothelium and its alterations in cardiovascular diseases: life style intervention. Biomed Res Int. 2014; 2014: 801896.
    CrossRefPubMed
  32. Mendoza-Núñez VM, García-Martínez BI, Rosado-Pérez J, et al. The Effect of 600 mg Alpha-lipoic Acid Supplementation on Oxidative Stress, Inflammation, and RAGE in Older Adults with Type 2 Diabetes Mellitus. Oxid Med Cell Longev. 2019; 2019: 3276958.
    CrossRefPubMed
  33. Packer L, Roy S, Sen CK. α-Lioic acid: a metabolic antioxidant and otential redox modulator of transcrition. Adv Pharmacol. 1996; 38: 79–101.
    CrossRef
  34. Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995; 19(2): 227–250.
    CrossRefPubMed
  35. Heitzer T, Finckh B, Albers S, et al. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med. 2001; 31(1): 53–61.
    CrossRefPubMed
  36. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol. 1997; 29(3): 315–331.
    CrossRefPubMed
  37. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med. 2000; 343(16): 1179–1182.
    CrossRefPubMed
  38. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107(3): 391–397.
    CrossRefPubMed
  39. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999; 353(9165): 1649–1652.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl